

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virgiria 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/556,178	04/20/2000	Olga Bandman	PF-0417-2-DIV	5936
23-428 7590 00/1/2001 FOLEY AND LARDNER LLP SUITE 500 3000 K STREET NW WASHINGTON, DC 20007			EXAMINER	
			STRZELECKA, TERESA E	
			ART UNIT	PAPER NUMBER
			1637	
			MAIL DATE	DELIVERY MODE

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
Examiner-Initiated Interview Summary	09/556,178	BANDMAN ET AL.	
Examiner-initiated interview Summary	Examiner	Art Unit	
	TERESA E. STRZELECKA	1637	
All Participants:	Status of Application: Per	nding	
(1) <u>Teresa Strzelecka</u> .	(3)		
(2) Stephanie Vavra.	(4)		
Date of Interview: 17 December 2010	Time:		
Type of Interview:  ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant  Exhibit Shown or Demonstrated: ☐ Yes If Yes, provide a brief description:	nt's representative)		
Part I.			
Rejection(s) discussed:			
Claims discussed: Prior art documents discussed:			
Part II.			
SUBSTANCE OF INTERVIEW DESCRIBING THE GENER Ms. Vavra was informed that the results of sequence search for SNO, 3 and two sequences 99.5% and 99.2% identical to SEQ ID. allowable: amino acid sequences comprising at least 90% identify identify to SEQ ID NO.3 and amino acid sequences comprising at least 90% identify to SEQ ID NO.3 and amino acid sequences comprising at least 90% identify to SEQ ID NO.5, or to their biologic deleted, as they present written description and/or utility issues. Mamendments.	EQ ID NO: 3 and 5 revealed no s NO: 5. Examiner proposed that th v to SEQ ID NO: 1, amino acid se SEQ ID NO: 5. The limitations of cally-active fragments or immuno,	sequences identical to SEQ ID to following sequences are quences comprising 98% claim 1 drawn to sequences with genic fragments will need to be	
Part III.			
☐ It is not necessary for applicant to provide a separate or directly resulted in the allowance of the application. The of the interview in the Notice of Allowability. ☐ It is not necessary for applicant to provide a separate of did not result in resolution of all issues. A brief summary	examiner will provide a writte ecord of the substance of the	en summary of the substance interview, since the interview	
/Teresa E Strzelecka/ Primary Examiner, Art Unit 1637 December 17, 2010 (A	pplicant/Applicant's Representat	ive Signature – if appropriate)	